Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Toujeo
Pharma
Sanofi's sunny forecasts just might be achievable: analyst
New indications for Dupixent, coupled with the leveling off of revenue declines in diabetes, should help Sanofi meet its goals, analysts predict.
Arlene Weintraub
Feb 13, 2020 11:07am
Novo's Tresiba misses main mark in head-to-head Toujeo tilt
Sep 19, 2019 11:11am
Sanofi's Toujeo tops Tresiba in tough-to-treat diabetes group
Jun 10, 2019 11:05am
Sanofi unveils $99-per-month insulin subscription program
Apr 10, 2019 5:00am
Novo's Tresiba snags FDA nod highlighting hypo safety
Mar 26, 2018 11:15am
Sanofi's diabetes sales hit hard by PBM formulary moves
Feb 7, 2018 11:47am
